{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:57:10Z","timestamp":1761101830769},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,6,14]],"date-time":"2008-06-14T00:00:00Z","timestamp":1213401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1007\/s00223-008-9143-4","type":"journal-article","created":{"date-parts":[[2008,6,13]],"date-time":"2008-06-13T12:55:19Z","timestamp":1213361719000},"page":"43-54","source":"Crossref","is-referenced-by-count":22,"title":["Changes of Bone Metabolism in Seven Patients with Gaucher Disease Treated Consecutively with Imiglucerase and Miglustat"],"prefix":"10.1007","volume":"83","author":[{"given":"P.","family":"Mikosch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. B.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,6,14]]},"reference":[{"key":"9143_CR1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ejim.2006.07.005","volume":"17","author":"A Mehta","year":"2006","unstructured":"Mehta A (2006) Epidemiology and natural history of Gaucher\u2019s disease. Eur J Intern Med 17:S2\u2013S5","journal-title":"Eur J Intern Med"},{"key":"9143_CR2","first-page":"17","volume-title":"Glycolipid storage disorders","author":"CE Hollak","year":"2004","unstructured":"Hollak CE, Pastores GM (2004) Type I Gaucher disease. In: Zimran A (ed) Glycolipid storage disorders. Adis Communications, Abington, pp 17\u201326"},{"key":"9143_CR3","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1259\/bjr.75.suppl_1.750002","volume":"1","author":"RJ Wentrup","year":"2002","unstructured":"Wentrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B (2002) Skeletal aspects of Gaucher disease: a review. Br J Radiol 75 Suppl 1:A2\u2013A12","journal-title":"Br J Radiol 75 Suppl"},{"key":"9143_CR4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.0009-9163.2004.00217.x","volume":"65","author":"DP Germain","year":"2004","unstructured":"Germain DP (2004) Gaucher\u2019s disease: a paradigm for interventional genetics. Clin Genet 65:77\u201386","journal-title":"Clin Genet"},{"key":"9143_CR5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","volume":"122","author":"GA Grabowski","year":"1995","unstructured":"Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, Parker C, Schiffmann R, Hill SC, Brady RO (1995) Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant resources. Ann Intern Med 122:33\u201339","journal-title":"Ann Intern Med"},{"key":"9143_CR6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/qjmed\/91.7.483","volume":"91","author":"D Elstein","year":"1998","unstructured":"Elstein D, Abrahamov A, Hadas-Halpern I, Meyer A, Zimran A (1998) Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease. QJM 91:483\u2013488","journal-title":"QJM"},{"key":"9143_CR7","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0140-6736(95)91037-9","volume":"345","author":"CE Hollak","year":"1995","unstructured":"Hollak CE, Aerts JM, Goudsmit R, Phoa SS, Ek M, van Weely S, von dem Borne AE, van Oers MH (1995) Individualised low-dose alglucerase therapy for type 1 Gaucher disease. Lancet 345:1474\u20131478","journal-title":"Lancet"},{"key":"9143_CR8","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/blood.V82.2.408.408","volume":"82","author":"GM Pastores","year":"1993","unstructured":"Pastores GM, Sibille AR, Grabowski GA (1993) Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24\u00a0months. Blood 82:408\u2013416","journal-title":"Blood"},{"key":"9143_CR9","doi-asserted-by":"crossref","first-page":"A37","DOI":"10.1259\/bjr.75.suppl_1.750037","volume":"1","author":"B Bembi","year":"2002","unstructured":"Bembi B, Ciana G, Mengel E, Terk MR, Martini C, Wentrup RJ (2002) Bone complications in children with Gaucher disease. Br J Radiol 75 Suppl 1:A37\u2013A44","journal-title":"Br J Radiol 75 Suppl"},{"key":"9143_CR10","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0140-6736(94)90462-6","volume":"344","author":"B Bembi","year":"1994","unstructured":"Bembi B, Zanatta M, Carrozzi M, Baralle F, Gornati R, Berra B, Agosti E (1994) Enzyme replacement treatment in type 1 and type 3 Gaucher\u00b4s disease. Lancet 344:1679\u20131682","journal-title":"Lancet"},{"key":"9143_CR11","first-page":"703","volume":"91","author":"P Giraldo","year":"2006","unstructured":"Giraldo P, Latre P, Alfonso P, Acedo A, Alonso D, Barez A, Corrales A, Franco R, Roldan V, Serrano S, Pocovi M (2006) Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher\u00b4s disease. Hematologica 91:703\u2013706","journal-title":"Hematologica"},{"key":"9143_CR12","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:BOLI.0000045756.54006.17","volume":"27","author":"D Elstein","year":"2004","unstructured":"Elstein D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM, Lachmann RH, Hrebicek M, Platt FM, Butters TD, Dwek RA, Zimran A (2004) Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 27:757\u2013766","journal-title":"J Inherit Metab Dis"},{"key":"9143_CR13","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.clinthera.2005.08.004","volume":"27","author":"GM Pastores","year":"2005","unstructured":"Pastores GM, Barnett NL, Kolodny EH (2005) An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24\u00a0months of treatment. Clin Ther 27:1215\u20131227","journal-title":"Clin Ther"},{"key":"9143_CR14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1399-0004.2007.00769.x","volume":"71","author":"J Charrow","year":"2007","unstructured":"Charrow J, Dulisse B, Grabowski GA, Weinreb NJ (2007) The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 71:205\u2013211","journal-title":"Clin Genet"},{"key":"9143_CR15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s002560100375","volume":"30","author":"LW Poll","year":"2001","unstructured":"Poll LW, Koch JA, vom Dahl S, Willers R, Scherer A, Boerner D, Niederau C, Haussinger D, Modder U (2001) Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results. Skeletal Radiol 30:496\u2013503","journal-title":"Skeletal Radiol"},{"key":"9143_CR16","doi-asserted-by":"crossref","first-page":"A25","DOI":"10.1259\/bjr.75.suppl_1.750025","volume":"1","author":"LW Poll","year":"2002","unstructured":"Poll LW, Maas M, Terk MR, Roca-Espiau M, Bembi B, Ciana G, Weinreb NJ (2002) Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol 75(Suppl 1):A25\u2013A36","journal-title":"Br J Radiol 75 Suppl"},{"key":"9143_CR17","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1182\/blood-2005-12-5072","volume":"108","author":"M Fost de","year":"2006","unstructured":"de Fost M, Hollak CE, Groener JE, Aerts JM, Maas M, Poll LW, Wiersma MG, Haussinger D, Brett S, Brill N, vom Dahl S (2006) Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood 108:850\u2013855","journal-title":"Blood"},{"key":"9143_CR18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1359\/jbmr.061004","volume":"21","author":"RJ Wenstrup","year":"2007","unstructured":"Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner T (2007) Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res 21:119\u2013126","journal-title":"J Bone Miner Res"},{"key":"9143_CR19","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1399-0004.2007.00811.x","volume":"71","author":"N Weinreb","year":"2007","unstructured":"Weinreb N, Barranger J, Packman S, Prakash-Cheng A, Rosenbloom B, Sims K, Angell J, Skrinar A, Pastores GM (2007) Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet 71:576\u2013588","journal-title":"Clin Genet"},{"key":"9143_CR20","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.clinthera.2007.08.006","volume":"29","author":"G Pastores","year":"2007","unstructured":"Pastores G, Elstein D, Hrebicek M, Zimran A (2007) Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational open-label studies. Clin Ther 29:1645\u20131654","journal-title":"Clin Ther"},{"key":"9143_CR21","doi-asserted-by":"crossref","unstructured":"Ciana G, Addobbati R, Tamaro G, Leopaldi A, Nevyiel M, Ronfani L, Vidoni L, Pittis MG, Bembi B (2005) Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J Inherit Metab Dis 28:723\u2013732","DOI":"10.1007\/s10545-005-0032-y"},{"key":"9143_CR22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00223-001-2072-0","volume":"72","author":"G Ciana","year":"2003","unstructured":"Ciana G, Martini C, Leopaldi A, Tamoro G, Katouzian F, Ronfani L, Bembi B (2003) Bone marker alterations in patients with type 1 Gaucher disease. Calcif Tissue Int 72:185\u2013189","journal-title":"Calcif Tissue Int"},{"key":"9143_CR23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1006\/bcmd.2001.0479","volume":"28","author":"C Drugan","year":"2002","unstructured":"Drugan C, Jebeleanu G, Grigorescu-Sido P, Caillaud C, Craciun AM (2002) Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease. Blood Cells Mol Dis 28:13\u201320","journal-title":"Blood Cells Mol Dis"},{"key":"9143_CR24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s774-002-8444-1","volume":"20","author":"CE Fiore","year":"2002","unstructured":"Fiore CE, Barone R, Pennisi P, Pavone V, Riccobene S (2002) Bone ultrasonometry, bone density, and bone turnover markers in type 1 Gaucher disease. J Bone Miner Metab 20:24\u201338","journal-title":"J Bone Miner Metab"},{"key":"9143_CR25","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.ejim.2006.07.003","volume":"17","author":"A Mehta","year":"2006","unstructured":"Mehta A (2006) Clinical experience with substrate reduction therapy. Eur J Intern Med 17:S13\u2013S15","journal-title":"Eur J Intern Med"},{"key":"9143_CR26","doi-asserted-by":"crossref","first-page":"330","DOI":"10.12968\/bjon.2006.15.6.20681","volume":"15","author":"A Milligan","year":"2006","unstructured":"Milligan A, Hughes D, Goodwin S, Richfield L, Mehta A (2006) Intraveneous enzyme replacement therapy: better in home or hospital? Br J Nurs 15:330\u2013333","journal-title":"Br J Nurs"},{"key":"9143_CR27","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2292020296","volume":"229","author":"M Maas","year":"2003","unstructured":"Maas M, van Kuijk C, Stoker J, Hollak CE, Akkerman EM, Aerts JF, den Heeten GJ (2003) Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging\u2014initial experience. Radiology 229:554\u2013561","journal-title":"Radiology"},{"key":"9143_CR28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/qjmed\/90.1.19","volume":"90","author":"MJ Allen","year":"1997","unstructured":"Allen MJ, Myer BJ, Khokher AM, Rushton N, Cox TM (1997) Pro-inflammatory cytokines and the pathogenesis of Gaucher\u2019s disease: increased release of interleukin-6 and interleukin-10. QJM 90:19\u201325","journal-title":"QJM"},{"key":"9143_CR29","first-page":"205","volume":"10","author":"V Barak","year":"1999","unstructured":"Barak V, Acker M, Nisman B, Kalickman I, Abrahamov A, Zimran A, Yatziv S (1999) Cytokines in Gaucher\u2019s disease. Eur Cytokine Netw 10:205\u2013210","journal-title":"Eur Cytokine Netw"},{"key":"9143_CR30","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.bbadis.2007.04.002","volume":"1772","author":"MJ Breemen","year":"2007","unstructured":"Breemen MJ, de Fost M, Voerman JS, Laman JD, Boot RG, Maas M, Hollak CE, Aerts JM, Rezaee F (2007) Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochim Biophys Acta 1772:788\u2013796","journal-title":"Biochim Biophys Acta"},{"key":"9143_CR31","doi-asserted-by":"crossref","first-page":"7260","DOI":"10.1073\/pnas.87.18.7260","volume":"87","author":"N Udagawa","year":"1990","unstructured":"Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T, Koga T, Martin TJ, Suda T (1990) Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA 87:7260\u20137264","journal-title":"Proc Natl Acad Sci USA"},{"key":"9143_CR32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","volume":"41","author":"GM Pastores","year":"2004","unstructured":"Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M et\u00a0al (2004) Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 41:4\u201314","journal-title":"Semin Hematol"},{"key":"9143_CR33","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","volume":"357","author":"MF Holick","year":"2007","unstructured":"Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266\u2013281","journal-title":"N Engl J Med"},{"key":"9143_CR34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/jn\/135.2.317","volume":"135","author":"BW Hollis","year":"2005","unstructured":"Hollis BW (2005) Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 135:317\u2013322","journal-title":"J Nutr"},{"key":"9143_CR35","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1079\/BJN2003837","volume":"89","author":"A Zittermann","year":"2003","unstructured":"Zittermann A (2003) Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 89:552\u2013572","journal-title":"Br J Nutr"},{"key":"9143_CR36","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/bcmd.1997.0137","volume":"23","author":"CE Hollak","year":"1997","unstructured":"Hollak CE, Evers L, Aerts JM, van Oers MH (1997) Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 23:201\u2013212","journal-title":"Blood Cells Mol Dis"},{"key":"9143_CR37","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1185\/030079906X104623","volume":"22","author":"S vom Dahl","year":"2006","unstructured":"vom Dahl S, Poll L, Di Rocco M, Ciana G, Denes C, Mariani G, Maas M (2006) Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients. Curr Med Res Opin 22:1045\u20131064","journal-title":"Curr Med Res Opin"},{"key":"9143_CR38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0009-9120(99)00098-3","volume":"33","author":"B Czartoryska","year":"2000","unstructured":"Czartoryska B, Tylki-Szyma\u0144ska A, Lugowska A (2000) Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease. Clin Biochem 33:147\u2013149","journal-title":"Clin Biochem"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-008-9143-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-008-9143-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-008-9143-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T09:30:23Z","timestamp":1709026223000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-008-9143-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,14]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["9143"],"URL":"https:\/\/doi.org\/10.1007\/s00223-008-9143-4","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,14]]}}}